Limits...
Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus

Pancreatic level of Th1 cytokines TNF-α and IL-1β in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) prevented increase in TNF-α (A) and IL-1β (B) in pancreas sample of treated mice*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298332&req=5

Figure 3: Pancreatic level of Th1 cytokines TNF-α and IL-1β in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) prevented increase in TNF-α (A) and IL-1β (B) in pancreas sample of treated mice*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C

Mentions: Two Th1 cytokines, IL-1β and TNF-α, were assessed at the end of the study in the pancreas sample of mice. Results are shown in Figure 3. As seen, there are significant differences in concentration of both cytokines in diabetic mice. IMOD™ could lead to lower production of IL-1β and TNF-α in pancreas of treated mice.


Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Pancreatic level of Th1 cytokines TNF-α and IL-1β in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) prevented increase in TNF-α (A) and IL-1β (B) in pancreas sample of treated mice*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298332&req=5

Figure 3: Pancreatic level of Th1 cytokines TNF-α and IL-1β in experimental groups on day 21. IMOD™ (20 mg/kg/d, IP) prevented increase in TNF-α (A) and IL-1β (B) in pancreas sample of treated mice*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
Mentions: Two Th1 cytokines, IL-1β and TNF-α, were assessed at the end of the study in the pancreas sample of mice. Results are shown in Figure 3. As seen, there are significant differences in concentration of both cytokines in diabetic mice. IMOD™ could lead to lower production of IL-1β and TNF-α in pancreas of treated mice.

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus